^™middle.

Gathering signals...

Ceretas (ASX:CTS) — Material Events

ASX:CTS · 3 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed

Significant Score 75–89

2

Ceretas Limited Launches $8 Million IPO to Advance Alzheimer’s Ultrasound TherapyHigh

Ceretas Limited launches $8 million IPO to fund clinical trials and development of therapeutic ultrasound device for Alzheimer's treatment

21 July 2026 ·Prospectus ·85

Ceretas Reports $1.63 Million Loss as $8 Million IPO Fuels Alzheimer’s Ultrasound Device ProgressMedium

Ceretas Limited reports FY26 loss of $1.63 million on $1.28 million revenue, completes $8 million IPO to fund Alzheimer's-focused ultrasound device development

31 Aug 2026 ·Annual Report and Financial Statements ·80

Notable Score 50–74

1

Ceretas Unlocks $692,578 After Completing Alzheimer’s Device MilestoneMedium

Ceretas completes CUREator+ milestone and unlocks $692,578 funding tranche

16 Sept 2026 ·Milestone Update and Grant Funding ·74

Not Assessed Low Score, or missing data

0

No articles in this tier for the last 12 months.

Market Mentions 2 - appeared in market wrap coverage

These are market wrap articles where Ceretas (ASX:CTS) was mentioned. They reflect broader market coverage, not company-specific announcements.

Healthcare Wrap - Week 36 (31 Aug -> 4 Sept) 2026

Healthcare Wrap - Week 30 (20 July -> 24 July) 2026